Form 4: CONMED Executive John D. Ferrell Granted Stock Options
SEC Form 4 Filing
John D. Ferrell, Executive Vice President HR of CONMED Corp, was granted 11,250 stock options on March 1, 2024, under the company's 2018 Long-Term Incentive Plan.
Summary
- On March 1, 2024, John D. Ferrell, Executive Vice President HR of CONMED Corp, was granted 11,250 stock options.
- The options were granted under the company's 2018 Long-Term Incentive Plan.
- The exercise price of the options is $79.95.
- The options vest in equal amounts over a five-year period.
- The options expire on March 1, 2034.
- A power of attorney was previously established on September 13, 2023, authorizing Heather L. Cohen, Lindsey F. Brewer, and Thomas Fistek to act on behalf of John D. Ferrell for Section 16 and Rule 144 filings.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation. It is neither particularly positive nor negative, but reflects standard corporate governance practices.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the medical device industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the medical technology industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their long-term incentive plans for executives.
- The vesting schedule of five years is fairly standard for stock options in this sector.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the executive's performance leads to an increase in the company's stock price.
- The grant incentivizes the executive to contribute to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 2023-09-13 | Date of Limited Power of Attorney execution. |
| 2024-03-01 | Date of stock options grant. |
| 2024-03-05 | Date of Form 4 signature. |
| 2034-03-01 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.